#NewAseBioMember | "AseBio is the main meeting point for the biotechnology sector in Spain"

AseBio. What does your company's work bring to the table and what is its strength?

Fernando García Osorio. Arquea Biological Innovations develops rapid, on-site pathogen detection solutions for the agri-food and veterinary industries. We have developed and patented our own molecular analysis technology (AMP-LAMP®), together with a portable device capable of delivering results in under one hour, compared to the more than 24 hours required by conventional microbiological methods.

Our strength lies not only in the technology itself, but in how we translate it into real-world use. We integrate molecular development, validation in industrial environments, and digitalization of results into a single workflow. It is not just about faster analysis, but about turning every result into an operational decision. This enables our clients to monitor their production processes in real time, with a direct impact on costs, timelines, and audit requirements.

AseBio. What is AseBio for you?

Fernando García Osorio. AseBio is the main meeting point for the biotechnology sector in Spain. For Arquea, joining AseBio is a way to be present in the forum where the future of the sector is shaped, in dialogue with investors, regulators, and other key ecosystem stakeholders.

Moreover, this comes at a particularly relevant time for us, as we are in the midst of commercial expansion and opening up to institutional investment, where visibility and positioning are especially important.

AseBio. When did you first hear about AseBio?

Fernando García Osorio. We first became aware of AseBio through the European Business and Innovation Centre of Asturias (CEEI Asturias) and Asturex, which led us to participate in BIOSPAIN 2025. Since then, it has been a constant reference as the representative association of the biotechnology sector in Spain in our conversations with investors, partners, and R&D stakeholders.

AseBio. What do you expect from being part of an association like AseBio?

Fernando García Osorio. We see the impact across three main areas: access to a network of companies, research centers, and investors with shared challenges and perspectives; increased visibility at a key stage of growth; and the opportunity to participate in discussions that directly shape the future of our business—particularly in regulation and innovation in areas such as pathogen detection, traceability, and food safety.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Fernando García Osorio. The main challenge remains the asymmetry between the pace of innovation and the speed of the market. At Arquea, we can design and validate a disruptive solution—targeting virtually any pathogen—within hours, yet regulatory and certification processes can take months or even years. This creates a significant financial burden and forces highly selective strategic prioritization.

This gap is, in our view, a broader issue across the biotech sector and particularly penalizes emerging companies compared to larger corporations. While we have strong innovation capabilities and the ability to address critical challenges, we face slow and complex barriers to entry. Reducing these regulatory barriers is essential to achieving real impact across the industrial value chain.